KZIA Stock Overview Operates as an oncology-focused biotechnology company in South Korea. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Kazia Therapeutics Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Kazia Therapeutics Historical stock prices Current Share Price US$3.02 52 Week High US$15.80 52 Week Low US$1.87 Beta 1.99 1 Month Change -45.86% 3 Month Change -23.39% 1 Year Change -32.89% 3 Year Change -96.43% 5 Year Change -93.27% Change since IPO -99.81%
Recent News & Updates
Kazia Therapeutics Limited Announces to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium Dec 12
Kazia Therapeutics Limited Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme Nov 05
Kazia Therapeutics Limited announced delayed 20-F filing Nov 03 Kazia Therapeutics Limited announced delayed 20-F filing Nov 02
New minor risk - Financial data availability Oct 13
Kazia Therapeutics Limited Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting Oct 02 See more updates
Kazia Therapeutics Limited Announces to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium Dec 12
Kazia Therapeutics Limited Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme Nov 05
Kazia Therapeutics Limited announced delayed 20-F filing Nov 03 Kazia Therapeutics Limited announced delayed 20-F filing Nov 02
New minor risk - Financial data availability Oct 13
Kazia Therapeutics Limited Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting Oct 02
Kazia Therapeutics Announces Presentation of Evt801 Clinical Data At 15 Biennial Ovarian Cancer Research Symposium Sep 26
New major risk - Market cap size Sep 18 Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $10 million. Sep 06
Kazia Therapeutics Limited Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma Jul 10
Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients May 01 Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP Apr 20
New major risk - Share price stability Apr 19
New major risk - Financial position Mar 27
New minor risk - Financial data availability Mar 18
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint Feb 21
Kazia Therapeutics Limited Announces Appointment of Board Members Jan 18 Kazia Therapeutics Limited Announces Executive Changes
New major risk - Revenue and earnings growth Dec 18
New major risk - Shareholder dilution Dec 06 Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million. Dec 06
Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification Nov 22
High number of new and inexperienced directors Nov 17
Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma Nov 02
Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study Oct 24
Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting Oct 01
Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023 Aug 31
Kazia Therapeutics Limited Announces Change to Board of Directors Aug 12
Kazia Therapeutics Limited Announces Change to Board of Directors Aug 11
Kazia Therapeutics Limited Appoints John Friend as Managing Director Aug 01 Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million. Jul 14
Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy Jul 07
Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma Jun 09
Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board Jun 05
Kazia Announces Receipt of Nasdaq Minimum Bid Notification Dec 13
Kazia Therapeutics Announces the Publication of Pre-Clinical Data for Its Second Pipeline Asset, EVT801 in the Journal Cancer Research Communications Dec 10
Kazia Therapeutics Limited Announces Publication of Positive Preclinical Data for Evt801 Dec 01
Kazia Therapeutics Limited's Paxalisib Demonstrates Positive Monotherapy Efficacy Signals in Preclinical Models of Melanoma Oct 28
Kazia Therapeutics Limited Announces Expansion of PNOC Study into Australia Oct 07
Kazia Therapeutics Limited, Annual General Meeting, Nov 16, 2022 Sep 27
Kazia Therapeutics Limited Presents Promising New Data from an Ongoing Phase I Clinical Trial of Paxalisib in Combination with Radiotherapy Aug 06
Kazia Therapeutics Limited Provides Progress Update on GBM Agile Pivotal Study Aug 02
Kazia Therapeutics Limited Launches New Scientific Advisory Board Jul 13
Kazia Therapeutics Limited Launches New Scientific Advisory Board Jul 12
United States Food and Drug Administration Awards Rare Pediatric Disease Designation to Kazia Therapeutics Limited's Paxalisib for AT/RT, Rare Form of Childhood Brain Cancer Jul 07
Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy Jul 06
Kazia Therapeutics Limited Provides Progress Update on Paxalisib and EVT801 Clinical Programs Jun 30
Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Brain Metastases Advances to Expansion Stage in Breast Cancer Brain Metastases Cohort Jun 08
Kazia Presents Positive Final Data from Phase II Study of Paxalisib in Newly Diagnosed Glioblastoma at ASCO Conference Jun 04
Kazia to Present Final Data from Paxalisib Phase II Study in Glioblastoma At ASCO May 02
Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Glioblastoma Achieves Final Completion Apr 21
Kazia Presents Preclinical Data for Paxalisib At AACR Apr 08
Kazia Therapeutics Limited Announces Phase II Clinical Study at Weill Cornell Medical Center Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet Enrolls First Patient Mar 01
Kazia Therapeutics Limited Announces First Patient Enrolls in Phase II Clinical Study Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet Feb 28
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0395 (Paxalisib) Issued by Thenational Medical Products Administration Under Collaboration with Kazia Therapeutics Limited Dec 08
Kazia Releases Final Data from P2 Paxalisib Trial Dec 05
Kazia Therapeutics Limited Provides Progress Update on Paxalisib and Evt801 Clinical Programs Jul 01
Kazia Therapeutics Limited Announces Manufacturing Patents Granted for Paxalisib in Key Territories Jun 25
Kazia Therapeutics Limited Launches New Paxalisib Phase II Clinical Trial Jun 15
Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial Jun 15
Kazia Therapeutics Limited Announces Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient Jun 08
Enrollment gets underway in Kazia's mid-stage lymphoma study Jun 07
Kazia Therapeutics Limited announced that it expects to receive AUD 5.2 million in funding from Simcere Pharmaceutical Group Limited Mar 31
Kazia Licenses Cantrixil, to Oasmia Pharmacetical AB Mar 03 Kazia Therapeutics Limited Announces GBM AGILE Pivotal Study Commences Recruitment to Paxalisib Arm
Kazia Therapeutics Limited to Collaborate with Pacific Pediatric Neuro-Oncology Consortium for New Paxalisib Combination Study in DIPG Dec 11
Kazia Therapeutics Limited Announces Top-Line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals Dec 10
Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer Dec 10
Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study Dec 09
Kazia Therapeutics Limited Presents Further Paxalisib Data At SNO, Confirming Earlier Positive Safety and Efficacy Signals in Glioblastoma Nov 19
Kazia stock +22% on positive paxalisib data in glioblastoma Nov 18
Kazia Therapeutics Limited Executes Agreement to Commence GBM Agile Pivotal Study Oct 16
Kazia Therapeutics Limited Enters into Collaboration with Dana-Farber Cancer Institute in the United States to Investigate the Use of Kazia’S Investigational New Drug, Paxalisib Sep 24
Kazia Therapeutics Limited Enter New Collaboration with Dana-Farber Cancer Institute Sep 22
US FDA Awards Orphan Drug Designation to Paxalisib for Malignant Glioma, Including DIPG Sep 17
Kazia Therapeutics Limited Auditor Raises 'Going Concern' Doubt Sep 08 Shareholder Returns KZIA US Biotechs US Market 7D -0.3% 2.1% 2.8% 1Y -32.9% -3.8% 24.5%
See full shareholder returns
Return vs Industry: KZIA underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: KZIA underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is KZIA's price volatile compared to industry and market? KZIA volatility KZIA Average Weekly Movement 23.6% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.1% 10% least volatile stocks in US Market 3.1%
Stable Share Price: KZIA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KZIA's weekly volatility has decreased from 42% to 24% over the past year, but is still higher than 75% of US stocks.
About the Company Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors.
Show more Kazia Therapeutics Limited Fundamentals Summary How do Kazia Therapeutics's earnings and revenue compare to its market cap? KZIA fundamental statistics Market cap US$12.67m Earnings (TTM ) -US$16.66m Revenue (TTM ) US$1.54m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) KZIA income statement (TTM ) Revenue AU$2.48m Cost of Revenue AU$0 Gross Profit AU$2.48m Other Expenses AU$29.26m Earnings -AU$26.78m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -6.15 Gross Margin 100.00% Net Profit Margin -1,079.32% Debt/Equity Ratio -6.3%
How did KZIA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 01:08 End of Day Share Price 2024/12/26 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Kazia Therapeutics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution John Hester Bell Potter Soo Romanoff Edison Investment Research Swayampakula Ramakanth H.C. Wainwright & Co.
Show 0 more analysts 
